Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cardinal Health Inc. said its top line rose 13% in its recently completed quarter, with gains for its pharmaceutical business offsetting a decline in its medical segment.

Cardinal Health Quarterly Sales Up 13%

Cardinal Health topped first-quarter estimates on Friday and maintained its adjusted EPS view, leading CAH stock to rise. The post Cardinal Health Inches Higher On First-Quarter Beat, Maintained Guidance appeared first on Investor's Business Daily.

Cardinal Health Inches Higher On First-Quarter Beat, Maintained Guidance

Shares of Cardinal Health Inc. CAH, +0.83% jumped 4.4% toward a five-year high in premarket trading Friday, after the drug and laboratory products distributor reported fiscal first-quarter profit and revenue that beat expectations, as strength in generics and branded pharmaceuticals helped offset inflationary supply chain costs. Net income for the quarter to Sept.

Cardinal Health stock jumps toward 5-year high after big profit and revenue beats, affirmed outlook

Revenue increased 13% to $49.6 billion GAAP 1 operating earnings were $137 million, GAAP diluted EPS were $0.40 Non-GAAP operating earnings decreased 20% to $423 million due to a decline in Medical segment profit, partially offset by an increase in Pharmaceutical segment profit; non-GAAP diluted EPS decreased 7% to $1.20 Company reaffirmed fiscal year 2023 non-GAAP EPS guidance DUBLIN, Ohio , Nov. 4, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported first quarter fiscal year 2023 revenues of $49.6 billion, an increase of 13% from the first quarter of last year. First quarter GAAP operating earnings were $137 million, including a non-cash, pre-tax goodwill impairment charge of $154 million in the Medical segment.

Cardinal Health Reports First Quarter Fiscal 2023 Results

DraftKings

The three major U.S. equity indexes closed lower on Tuesday. The Dow Jones industrials ended the day down 0.24%, the S&P 500 closed 0.41% lower and the Nasdaq retreated 0.89%.

Earnings Previews: Cardinal Health, DraftKings

Cardinal Health's (CAH) first-quarter fiscal 2023 results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.

Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?

Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Cardinal Health (CAH) to Report a Decline in Earnings: What to Look Out for

Genuine Parts

Cheniere Energy

Steel Dynamics

Vertex Pharmaceuticals

S&P 500 giant Vertex and Cheniere Energy, the largest U.S. liquefied natural gas producer, are setting up bullishly in the bear market. The post S&P 500 Biotech Giant Vertex Leads 5 Stocks Showing Strength appeared first on Investor's Business Daily.

S&P 500 Biotech Giant Vertex Leads 5 Stocks Showing Strength

American Airlines

Bunge Global SA

CVR Energy

Delta Air Lines

Broker-favorite stocks like American Airlines (AAL), Delta (DAL), CVR Energy (CVI), Bunge Limited (BG) and Cardinal Health (CAH) should be on an investor's watch list.

Check 5 Broker-Friendly Stocks for Returns Amid Market Chaos

Cardinal Health, which distributes branded and generic pharmaceuticals and other healthcare products, cleared a cup-with-handle buy point Wednesday.

Cardinal Health Clears Base, But Can It Maintain Uptrend?

DUBLIN, Ohio , Oct. 19, 2022 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) released its third edition of Rheumatology Insights , a research report based on surveys with more than 100 rheumatologists nationwide that focuses on key trends impacting one of the fastest-growing areas of specialty medicine. The research revealed that rheumatologists are both more familiar with biosimilars and more comfortable prescribing them than they were in 2020, just in time for a wave of new biosimilars anticipated to hit the market in 2023.

New Cardinal Health research highlights rheumatologists' increasing confidence in biosimilars

Merck

AutoZone

Molina Healthcare

Dow Jones leader Merck is breaking out past a buy point while other top stocks to watch include AutoZone, Cardinal and Molina Healthcare. The post Dow Jones Leader Merck Breaks Out; 3 Other Top Stocks To Watch appeared first on Investor's Business Daily.

Dow Jones Leader Merck Breaks Out; 3 Other Top Stocks To Watch

CAH's constant and steady growth has continued, and the company is constantly finding new revenue streams. The balance sheet is very well managed, with long-term debt having been paid down by almost 50% over the past five years.

Cardinal Health Is Being Undervalued, Has Significant Upside In The Near Term

Shockwave Medical

One company is an industry disruptor with big upside potential, while the other is a huge, diversified company.

2 Medical Device Makers Crushing the Market

DoubleVerify Holdings

Neurocrine Biosciences

Paylocity Hlds

Wolfspeed

As the market indexes work through a downturn, Vertex is among nine stocks to watch showing relative strength. The post Vertex Among 9 Stocks To Watch In Struggling Market appeared first on Investor's Business Daily.

Vertex Among 9 Stocks To Watch In Struggling Market

Catalyst Pharmaceuticals

As the market indexes work through a downturn, Vertex is among eight stocks to watch showing relative strength. The post Vertex Among 8 Stocks To Watch In Struggling Market appeared first on Investor's Business Daily.

Vertex Among 8 Stocks To Watch In Struggling Market

AbbVie

Abbott Labs

Acadia Healthcare

AstraZeneca

Bristol-Myers

Cigna

CVS Health

Johnson & Johnson

Novavax

Novartis

Pfizer

Regeneron Pharmaceuticals

Teladoc

UnitedHealth Group

Health care stocks are traditionally a defensive play for investors in a falling market. It's a rich market with blue chip insurance providers, service providers, pharmaceutical companies, retailers, and tech players.

Health Care Stocks: Reviewing The Best Of The Industry

Enphase Energy

We're in the midst of a bear market. That's something investors haven't seen in quite some time.

3 Blue-Chip Stocks to Buy to Tap Into a Hidden Bull Market

DUBLIN, Ohio , Sept. 27, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release first-quarter financial results for its fiscal year 2023 on November 4, prior to the opening of trading on the New York Stock Exchange.

Cardinal Health to Announce First-Quarter Results for Fiscal Year 2023 on November 4

Under activist pressure, Cardinal Health has changes at the top with a new business review committee put in place for the board of directors. Cardinal Health's mighty pharmaceutical sector outshines its troubled medical business.

Cardinal Health: Aristocrat Heading For A Makeover

Aflac

Essex Property Trust

General Dynamics

Walmart

Exxon Mobil

In what will be known in the future as the pandemic years, the easy money and the government's spoon-fed liquidity made lots of new investors feel like they were genius and savvy traders.

Stock Market Could Plunge: These 7 Dividend Aristocrats Can Survive the Fall

Procter & Gamble

During times of heightened volatility, an established income stream is undoubtedly a major positive, allowing investors to offset losses in other positions and reap those sweet dividend payouts.

Seeking Income? Consider These 3 Dividend Aristocrats

Launching a New, Robust Offering Leveraging Cardinal Health's Advanced Practice Analytics Technology Platform and PayrHealth's Payor Contracting Solution. AUSTIN, Texas , Sept.

PayrHealth Announces Collaboration with Cardinal Health

Apple

American Electric Power Company

Chevron

Iron Mountain

Keurig Dr Pepper Inc

Microsoft

NortonLifeLock

Oracle

Principal Financial Group

Philip Morris

Tuesday's massive stock market meltdown should serve as a reminder to investors that in times of turmoil, it pays to own shares of companies that also pay you.

As markets wobble, buy the stocks that pay you back

News for Cardinal Health Stock (CAH)